Dementias Platform UK

What Dementias Platform UK does

Dementias Platform UK (DPUK) is a UK-based research infrastructure platform founded in 2014 and hosted by the University of Oxford, dedicated to accelerating the discovery of treatments, diagnostics, and prevention strategies for dementia. It operates as a publicly-funded, non-commercial platform rather than a revenue-generating business, with primary capital coming from the Medical Research Council (MRC, grant MR/T033371/1) and the National Institute for Health and Care Research (NIHR). DPUK has stated that it has generated over £100m of additional research funding across its portfolio, and reports a workforce in the 11-50 employee range.

The platform comprises four interlocking infrastructure layers: (1) the DPUK Data Portal, a free-to-access repository providing secure remote analysis of multimodal data from 3.5 million+ participants across 85+ cohort studies, harmonised via a proprietary C-Surv ontology; (2) a Trials Delivery Framework spanning 80+ UK clinical sites that precision-matches 71,000+ registered participants (Great Minds 13,000+ and Clinical Studies Register 58,000+) into dementia studies; (3) an Experimental Medicine Incubator that de-risks drug development, including the Deep and Frequent Phenotyping study (250 participants) and the 2023-launched MND Accelerator; and (4) supporting physical infrastructure comprising an 8-scanner nationwide PET-MR Imaging Network (5 scanners funded by DPUK), a 6-university Stem Cell Network offering iPSC capabilities, and Datathon/Academy training programmes.

DPUK's business model is principally grant-funded with free-to-access core services; the only disclosed commercial pricing is approximately £125 for the 5-day Advanced Health Data Academy, alongside pharmaceutical industry collaborations (MedImmune, Imanova, Ixico) and strategic partnerships with Alzheimer's Society, Alzheimer's Research UK, Gates Ventures, Join Dementia Research, UKDRI, the Davos Alzheimer's Collaborative, and the Global Alzheimer's Platform. The go-to-market is enterprise field-sales to academic and pharma research users via scientific publications, conferences, social channels, and a quarterly newsletter, while distribution of cohort data is product-led/self-serve through the Portal.

Name

Dementias Platform UK

Legal name

Dementias Platform UK

Website

https://www.dementiasplatform.uk

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Dementias Platform UK is a publicly-funded, University of Oxford-hosted research infrastructure platform providing dementia researchers worldwide with secure access to 3.5M+ cohort records, an 80+ site trial delivery framework, PET-MR imaging, and stem cell facilities.

Ownership category

akta.pro rank

Product category

Dementia Research Infrastructure

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

akta.pro secondary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

Keywords

• Dementia research infrastructure
• Cohort data platform
• Clinical trial delivery
• Brain imaging network
• Experimental medicine

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

1. Research Infrastructure Funding: DPUK is primarily funded through grants from the Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR). The platform provides free access to its infrastructure for researchers, with operations funded through public research funding. Additional funding has been generated through research programs - DPUK has generated over £100m of additional funding for research.
2. Pharmaceutical Industry Partnerships: DPUK collaborates with pharmaceutical companies through its Experimental Medicine Incubator and trials delivery services. Industry partners access research infrastructure, participant registries, and data for clinical trials and drug development research.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

Core offering

DPUK is a public-funded research infrastructure platform that provides academic and industry researchers with integrated access to dementia research resources, including a Data Portal containing over 3.5 million health records from 85+ cohort studies, a nationwide PET-MR Imaging Network, a Stem Cell Network, and a Trials Delivery Framework with 80+ UK clinical sites. Its core products are free to access for bona fide researchers, and the platform is funded through grants from the MRC and NIHR, supplemented by pharmaceutical industry partnerships.

Product overview

Dementias Platform UK (DPUK) is a comprehensive dementia research infrastructure platform consisting of multiple integrated components: the DPUK Data Portal as the core data repository providing access to multimodal datasets from over 50 cohort studies and 3.5 million participants; the Trials Delivery Framework which matches volunteers to dementia studies across 80+ UK clinical sites; the Experimental Medicine Incubator accelerating treatment development; and participant registers (Great Minds with 13,000+ volunteers and Clinical Studies Register with 58,000+ participants). Supporting infrastructure includes an Imaging Network of PET-MR scanners, a Stem Cell Network providing iPSC technology, and training programmes including Datathons and Health Data Analyst Academies. Key research programmes include the Deep and Frequent Phenotyping study and the MND Accelerator. The platform is funded by the Medical Research Council and operates from University of Oxford.

Differentiator

Problem solved

Functional benefit

Products and services

• DPUK Data Portal A free-to-access research data repository providing rapid, secure access to multimodal datasets and millions of health research records from over 50 cohort studies, enabling researchers worldwide to identify, apply for, and analyse cohort data in a secure remote environment.
• Trials Delivery Framework A national infrastructure that matches public volunteers to dementia research studies and clinical trials through precision-matching based on detailed genetic and observed characteristics, with over 80 clinical sites across the UK.
• Experimental Medicine Incubator A programme that accelerates and de-risks development of new treatments for dementia by supporting clinical research aimed at reducing time, cost and risk of drug development.
• Great Minds Register A register of over 13,000 highly characterised research volunteers recruited from Join Dementia Research and existing DPUK-affiliated cohort studies, enabling precision-matching for dementia studies and clinical trials.
• Clinical Studies Register A register of more than 58,000 research participants who have undergone extensive characterisation and have pre-existing consent for re-contact through their parent DPUK cohort.
• Stem Cell Network A network of stem cell laboratories based at Cambridge, Cardiff, Edinburgh, Manchester, Oxford, and UCL providing researchers access to iPSC technology, equipment, and expertise for dementia research projects.
• Imaging Network The first nationwide network of eight state-of-the-art PET-MR brain scanners (five funded by DPUK) enabling simultaneous acquisition of PET and MRI data for advanced brain imaging in dementia research.
• Deep and Frequent Phenotyping Study A landmark study recruiting 250 UK participants over 60 with family history of dementia, collecting regular brain scans, cognitive tests, MEG scans, retinal imaging, blood tests, and wearable technology data to identify early warning signs of Alzheimer's disease.
• DPUK Datathons Free 5-day online collaborative events where researchers work in multidisciplinary teams on dementia risk and progression questions using cohorts in the DPUK Data Portal, led by Dr Sarah Bauermeister.
• Health Data Analyst Academies Training academies at Elementary (beginner/foundation) and Advanced levels offering immersive statistical analytical skills through online week-long events presented with University of Edinburgh, covering cohort analysis techniques.
• MND Accelerator A £6 million investment programme by the Medical Research Council and National Institute for Health and Care Research to accelerate translation of discoveries into therapeutics for Motor Neurone Disease, managed by DPUK.

Quantifiable outcome

• Delaying dementia onset by 5 years could reduce the number of people with dementia by 35%
• +3 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

• Join Dementia ResearchcoreStrategic or Co-development PartnerNational initiative managed by NIHR for recruiting public volunteers into dementia research. DPUK works with JDR as the front-end for volunteer recruitment, linking participants to DPUK's precision-matching infrastructure.
• UK Dementia Research Institute (UKDRI)majorStrategic or Co-development PartnerUKDRI provides facilities for the MND Accelerator program managed by DPUK, contributing to the experimental medicine infrastructure.
• Brain Health CoalitionmajorStrategic or Co-development PartnerNetwork of Brain Health Centres working with DPUK's Trials Delivery Framework for clinical trial recruitment and brain health research.
• NIHR Dementia Translational Research Collaboration Trial NetworkmajorStrategic or Co-development PartnerNational network of dementia research sites collaborating with DPUK for clinical trial delivery.
• Dame Barbara Windsor Dementia MissionmajorStrategic or Co-development PartnerUK government initiative for dementia research working with DPUK's infrastructure for trial recruitment.
• Davos Alzheimer's CollaborativemajorStrategic or Co-development PartnerGlobal partnership working to accelerate dementia research collaboration internationally, aligned with DPUK's research infrastructure.
• Global Alzheimer's PlatformmajorStrategic or Co-development PartnerInternational network focused on accelerating Alzheimer's disease clinical trials, partnering with DPUK for UK site network.
• MedImmunemajorStrategic or Co-development PartnerPharmaceutical company partner in Deep and Frequent Phenotyping study, represented by Dr Tharani Chessell and Dr Iain Chessell as co-investigators.
• ImanovamajorStrategic or Co-development PartnerImaging research company partner providing PET imaging expertise in DFP study, with Prof Roger Gunn as PET lead and Dr Ilan Rabiner as co-investigator.
• IxicominorStrategic or Co-development PartnerImaging analytics company partner in Deep and Frequent Phenotyping study with Dr Derek Hill and Dr John Hall as co-investigators.
• Health Data Research UKmajorStrategic or Co-development PartnerPartnership aimed at linking NHS patient electronic health records with DPUK cohort data for major open-science resource.
• Alzheimer's Disease Data InitiativemajorTechnology or IntegrationData initiative aligned with DPUK through federation, connecting the Data Portal with the AD Workbench platform.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• UK Dementia Research Institute (UKDRI): UK's flagship dementia research institute, hosted across multiple universities. Directly comparable to DPUK as a UK-based, MRC-aligned dementia research infrastructure platform with overlapping principal investigators and shared programmes (e.g. MND Accelerator facilities).
• Global Alzheimer's Platform (GAP): International network focused on accelerating Alzheimer's clinical trials. Comparable to DPUK's Trials Delivery Framework in mission and operating model, but operates globally across multiple countries rather than being UK-centric.
• Alzheimer's Disease Neuroimaging Initiative (ADNI): Long-running longitudinal cohort and imaging study for Alzheimer's disease. Directly comparable to DPUK's Data Portal and Imaging Network, providing multimodal cohort data and PET-MR imaging standards used in dementia research worldwide.
• European Prevention of Alzheimer's Dementia (EPAD): European consortium building a readiness cohort for secondary prevention trials in Alzheimer's. Comparable to DPUK's Experimental Medicine Incubator and participant registries, with a similar focus on trial-ready, deeply phenotyped volunteers.
• Brain Health Registry (UCSF): Online registry recruiting participants for dementia and Alzheimer's trials. Directly comparable to DPUK's Great Minds register and Clinical Studies Register in offering precision-matched recruitment for dementia studies, though US-based.
• Alzheimer's Disease Data Initiative (ADDI) / AD Workbench: Global data-sharing platform for Alzheimer's and dementia research. Directly comparable to DPUK's Data Portal and is already integrated via federation; both pursue cross-cohort data harmonisation and sharing for the dementia research community.

Broad incumbents

• UK Biobank: Large-scale biomedical research resource with deep phenotypic and genomic data on 500,000+ participants. Comparable in operating model (cohort data, research access infrastructure, UK-hosted) but much broader in scope than DPUK's dementia focus.
• Health Data Research UK: UK-wide institute for health data science. DPUK is a formal partner; HDR UK's broader NHS electronic health record linkage ambitions overlap with DPUK's cohort data infrastructure and NHS data linkage plans.

Emerging players

• Davos Alzheimer's Collaborative: Global multi-stakeholder initiative to accelerate Alzheimer's research and treatment access. Comparable to DPUK in coordinating clinical and research infrastructure across geographies; DPUK is an active partner, and both aim to shorten the path from research to therapy.

Regional players

• Canadian Consortium for Neurodegeneration and Aging (CCNA): Canadian national consortium funding neurodegenerative disease research. Comparable to DPUK in operating as a national dementia research coordination platform, but focused on Canadian institutions and cohorts rather than competing in the UK market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/dementiasuk
• LinkedInlinkedin.com/company/dpuk

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dementias Platform UK